Novo Nordisk opens new plant in Medicon Valley  

A new plant for manufacturing Novo Seven comes on stream as part of a planned 8 year construction boom

Novo Nordisk has just opened a new DKK 1 billion (USD 130 million) production facility in Medicon Valley north of Copenhagen. Built in a record 18 months and a clone of its existing plant in Kalundborg, the new factory will produce the recombinant Factor VIIa haemophilia treatment Novo Seven. The facility is part of a 8 year construction boom planned by the company, involving a DKK 23.5 billion (USD 3 billion) investment. The reason behind the investment is that Novo Nordisk anticipates a strong increase in the sales of its insulin analogues and Factor VIIa product. The news is reported in Børsen and Berlingske Tidende today.


One of Denmark's major companies, Novo Nordisk is a world leader in diabetes care. The company employs approximately 17,500 people in 68 countries and markets its products in 179 countries.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×